Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?

Expert review of hematology - 1 Oct 2020

Bewersdorf Jan Philipp, Zeidan Amer M

Abstract excerpt

INTRODUCTION: Hypomethylating agents (HMA) remain the mainstay of treatment for patients with higher-risk myelodysplastic syndromes (HR-MDS). However, complete responses to HMAs are seen in <20% of cases and are typically not durable. For most patients, HMA failure is an eventual certainty that is associated with an abysmal prognosis. AREAS COVERED: PubMed and abstracts from annual meetings were searched in May...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Combined Modality Therapy
Share to Disease Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Development

Share to Molecular Targeted Therapy

Share to Myelodysplastic Syndromes

Share to Remission Induction

Share to Retreatment

Share to Treatment Failure

Source

Identifiers

PMID: 32876498
DOI: 10.1080/17474086.2020.1819233

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?PMID 32876498Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.Semantic proximity Read ↗

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Semantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Myelodysplastic Syndromes: A New Decade.Semantic proximity Read ↗

Optimizing hypomethylating agents in myelodysplastic syndromesSemantic proximity Read ↗

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.Semantic proximity Read ↗

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.Semantic proximity Read ↗

Current and emerging strategies for management of myelodysplastic syndromes.Semantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.Semantic proximity Read ↗

Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.